Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals has filed to terminate the registration of its common stock and suspend its reporting obligations under Section 12(g) of the Securities Exchange Act. The company confirmed that there is currently only one record holder of its common stock and has officially notified the SEC of this termination.…more
Crinetics Pharmaceuticals, Inc.
Wendell Wierenga, an insider at Crinetics Pharmaceuticals, filed a Form 4 on September 1, 2026, to report changes in beneficial ownership of securities. This filing serves as a standard disclosure of insider equity transactions.…more
Crinetics Pharmaceuticals, Inc.
Director Rogerio Vivaldi Coelho of Crinetics Pharmaceuticals filed a Form 4 on September 1, 2026, reporting changes in his beneficial ownership of company securities. This filing serves as a standard disclosure of insider equity transactions.…more
34 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
버텍스 파마슈티컬스, 크리네틱스 100억 달러에 인수
버텍스 파마슈티컬스가 크리네틱스를 주당 85달러, 총 100억 달러 규모에 인수하기로 합의했습니다. 이번 인수는 크리네틱스의 신약 파이프라인과 상업화 역량을 높게 평가한 결과로, 올해 3분기 내 완료될 예정입니다.…more